Furthermore, PAI‐1 is the principal fibrinolytic inhibitor in the pathogenesis of acute respiratory distress syndrome, representing an independent risk factor for poor prognosis and mortality in acute lung injury (ALI) [44, 45, 46], a condition that may develop COVID‐19 infection [1, 2, 3, 4]. Here, SERPINE1 is linked to acute respiratory distress syndrome.